All articles by  

  1. Novavax begins Phase III clinical trial for influenza vaccine NanoFlu

    US-based late-stage biotechnology company Novavax has started a pivotal Phase III clinical trial for its influenza vaccine, NanoFlu. NanoFlu is…
    Read More…

    16 Oct
  2. Gilead and Galapagos report data from filgotinib trials in RA

    US antiviral drugmaker Gilead Sciences and Belgo-Dutch biotech Galapagos have announced week 52 data from the Phase III FINCH 1…
    Read More…

    11 Oct
  3. Anavex initiates ANAVEX 2-73 study in Alzheimer disease

    Clinical-stage biopharmaceutical company Anavex Life Sciences has initiated a long-term extension study for patients with early Alzheimer’s disease (AD) and…
    Read More…

    10 Oct
  4. ESMO 2019: BeiGene presents data on tislelizumab and pamiparib

    Biopharmaceutical company BeiGene has presented data on its two investigational drug candidates, anti-PD-1 antibody tislelizumab and PARP inhibitor pamiparib. The…
    Read More…

    1 Oct
  5. Boehringer Ingelheim announces nintedanib trial met its primary endpoint

    Boehringer Ingelheim has presented data that shows the Phase III INBUILD trial of nintedanib met its primary endpoint. The drug…
    Read More…

    1 Oct
  6. AstraZeneca announces data from BRILINTA independent trial

    AstraZeneca has announced that new data from a Phase IV independent trial, TWILIGHT, showed BRILINTA (ticagrelor) monotherapy reduces the possibility…
    Read More…

    27 Sep
  7. Enanta sees topline results of EDP-305 ARGON-1 Phase 2a study for NASH

    Biotechnology company Enanta Pharmaceuticals has reported positive results from its ARGON-1 Phase 2a study of its lead product candidate EDP-305…
    Read More…

    26 Sep
  8. Zealand reports results of paediatric Phase 3 trial for hypoglycaemia

    Denmark-based biotechnology company Zealand Pharma has reported positive outcome for its dasiglucagon in the paediatric Phase 3 trial for severe…
    Read More…

    26 Sep
  9. Coordination Pharmaceuticals doses first patient in CPI-200 trial

    Coordination Pharmaceuticals (CPI) has dosed the first patient in a Phase I study of nanoscale coordination polymer (NCP) CPI-200 in…
    Read More…

    9 Aug
  10. Cincinnati Children’s new AI system reduces patient screening time

    Researchers at Cincinnati Children’s Hospital Medical Center in the US have designed and tested a new computerised solution which uses…
    Read More…

    26 Jul
Close
Close
Close

Go Top